Walvax Biotechnology Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was CNY 833.27 million compared to CNY 655.89 million a year ago. Revenue was CNY 833.27 million compared to CNY 655.89 million a year ago.

Net income was CNY 171.99 million compared to CNY 38.62 million a year ago. Basic earnings per share from continuing operations was CNY 0.1074 compared to CNY 0.0241 a year ago. Diluted earnings per share from continuing operations was CNY 0.1074 compared to CNY 0.0241 a year ago.